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Abstract
Acute myeloid leukemia is the most common form of acute leukemia in adults, constituting about 80% of cases.
Although remarkable progress has been made in the therapeutic scenario for patients with acute myeloid leukemia,
research and development of new and effective anticancer agents to improve patient outcome and minimize toxicity is
needed. In this study, the antitumor activity of axolotl (AXO) Ambystoma mexicanum crude extract was assessed in vitro
on the human acute myeloid leukemia HL-60 cell line. The anticancer activity was evaluated in terms of ability to influ-
ence proliferative activity, cell viability, cell cycle arrest, and differentiation. Moreover, gene expression analysis was per-
formed to evaluate the genes involved in the regulation of these processes. The AXO crude extract exhibited
antiproliferative but not cytotoxic activities on HL-60 cells, with cell cycle arrest in the G0/G1 phase. Furthermore, the
AXO-treated HL-60 cells showed an increase in both the percentage of nitroblue tetrazolium positive cells and the
expression of CD11b, whereas the proportion of CD14-positive cells did not change, suggesting that extract is able to
induce differentiation toward the granulocytic lineage. Finally, the treatment with AXO extract caused upregulation of
CEBPA, CEBPB, CEBPE, SPI1, CDKN1A, and CDKN2C, and downregulation of c-MYC. Our data clearly show the potential
anticancer activity of Ambystoma mexicanum on HL-60 cells and suggest that it could help develop promising therapeutic
agents for the treatment of acute myeloid leukemia.
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Introduction
Acute myeloid leukemia (AML) is a blood cancer char-
acterized by the proliferation of clonal precursor mye-
loid cells with differentiation arrest. AML is the most
common form of acute leukemia in adults constituting
about 80% of cases. Its incidence is about 1.3 per
100,000 for those below 65 years and about 12.2 cases
per 100,000 for those above 65.1
At present, standard intervention for AML consists
of chemotherapy and, secondarily, stem cell transplan-
tation. However, in many cases, AML cells are not
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eradicated, with persistent cells reappearing after a
period of remission. Also, the conventional therapies
have often shown undesirable side effects (e.g. hepato-
toxicity, myelosuppression, and tumor lysis syn-
drome).2 Thus, it is urgent to find new therapeutic
strategies for AML treatment.
Differentiation therapy, using agents that promote
cancer cell differentiation, has been shown to be effec-
tive in in vitro and in vivo treatment of several types of
cancers, including certain AML sub-types.3
In recent years, significant emphasis has been placed
on identifying new agents from natural sources that
could be used against cancer. Natural products,
extracted from abundant living organism sources, con-
tain bioactive compounds that have the potential for
prevention or treatment of major diseases. Many of
these have been identified to demonstrate diverse biolo-
gical actions, including anticancer activities.4 Therefore,
the screening of natural products against cancer is
needed.
The axolotl Ambystoma mexicanum is one of the
most widely used laboratory animals for stem cell
research and regeneration.5 The mechanisms governing
regeneration, wound healing, development, and cancer
formation are closely linked. There is increasing evi-
dence highlighting the common signaling pathways
which link cancer growth and regeneration whereby
dysregulation of the well-balanced and coordinated
process of regeneration leads to cancer. Thus, the iden-
tification of biologically active molecules from axolotl
extracts could lead to major benefits, with directions on
how to develop therapeutic approaches for cancer
treatment in humans. Interestingly, Allegrucci et al.6
found that axolotl oocyte extracts possess reprogram-
ming ability, which reverses epigenetic silencing of
tumor suppressor genes and tumorigenicity of breast
cancer cells in a mouse xenograft model.
This study was planned to establish the potential
anticancer activity of axolotl (AXO) Ambystoma mexi-
canum crude extract on human AML HL-60 cells. For
this purpose, we evaluated the effect of AXO crude
extract on cell proliferation, viability, cell cycle, and
differentiation of HL-60 cells, and determined whether
the AXO extract is able to modify the expression of
genes involved in the regulation of these processes.
Materials and methods
Animals and tissue collection
The procedure was adapted from McGann et al.7
Axolotls (A. mexicanum) were maintained in the
laboratory at 21C. Limb amputations were performed
on animals anesthetized transdermally with 0.1% tri-
caine in water. A hindlimb was amputated by cutting
just proximal to the elbow, and soft tissue was pushed
up the humerus to expose the bone. The bone and soft
tissue were trimmed to produce a flat amputation sur-
face. After amputation, the axolotls were placed on ice
for 1 h, transferred to a 0.5% sulfamerazine solution
overnight, and then back into their normal water envi-
ronment. After collection, all tissues were processed
immediately for preparation of the wet extract.
Preparation of wet extracts
Tissues collected were kept on ice during the prepara-
tion of wet extracts. They were transferred to 50mL
tubes containing 10mL sterile ice-cold Roswell Park
Memorial Institute (RPMI; Biowest, Meda, Monza and
Brianza, Italy) 1640 medium with 10% heat-inactivated
fetal bovine serum (FBS; Biowest). Three protease inhi-
bitors (2mg/mL leupeptin/2mg/mL aprotinin/1mM
phenylmethanesulfonyl fluoride (PMSF); Sigma-
Aldrich, Milan, Italy) were added to the medium. The
tissues were ground with an electronic tissue homogeni-
zer for 1 to 2min, hand homogenized in a sterile glass
homogenizer for 10 to 15min, and sonicated for 30 s in
succession. The wet preparation homogenate was trans-
ferred to 2mL microcentrifuge tubes, and the cell debris
was removed in two centrifugation steps, the first being
spun at 2000g for 25min at 4C. The supernatant was
collected and centrifuged again at 100,000g for 60min
at 4C. The final supernatant was filter-sterilized using
a 0.22mm filter and collected in a separate sterile 2mL
microcentrifuge tube. The protein content was assayed
using the detergent compatible (DC) protein assay kit
II (Bio-Rad Laboratories, Milan, Italy), and the tubes
were stored in 1mL aliquots in an280C freezer.
Cell culture
The human acute myeloid cell lines, HL-60 (ATCC-
CCL-240) and KG-1a (ATCC-CCL-246.1), were sup-
plied by the American Type Culture Collection (ATCC,
Manassas, VA, USA) and grown in RPMI 1640 medium
supplemented with 10% heat-inactivated FBS, 100U/mL
penicillin, and 100mg/mL streptomycin (Sigma-Aldrich).
Cells were incubated at 37C in a humidified atmosphere
with 5% CO2.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) was used to test the metabolic activity of
the cells. HL-60 and KG-1a cells (1 3 105 cells/well) were
seeded in 96-well plates and treated with different concen-
trations of AXO extract (0.25, 0.50, 1.00, and 2.00mg/
mL) for 24 to 72h. MTT solution (5mg/mL in
phosphate-buffered saline (PBS); Sigma-Aldrich) was
then added to each well and incubated for 4h at 37C,
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followed by the addition of 120mL of dimethyl sulfoxide
(DMSO). Finally, the plates were shaken and examined
using a microplate reader by measuring at a certain wave-
length (at 570nm, with 690nm as reference wavelength).
All experiments were repeated at least three times, and
each assay was performed in triplicate. Metabolic activity
was calculated as follows: Metabolic activity (%)=(OD
value of experimental samples/optical density [OD] value
of control samples) 3 100%.
Cell proliferation and viability by Trypan blue assay
HL-60 cells (1 3 105/well) were seeded in 48-well plates
and treated with different concentrations (0.25, 0.50,
1.00, and 2.00mg/mL) of AXO crude extract or 10%
of DMSO (Sigma-Aldrich) for 24 to 72h. Next, total
cell number and viability were evaluated by Trypan
blue exclusion assay using Countess II FL Automated
Cell Counter (Invitrogen by Thermo Fisher Scientific,
Waltham, MA, USA). Live cells excluded the dye,
whereas dead cells admitted the dye intensely staining
with Trypan blue.
Leishman staining
Cells (2 3 104/well) were seeded in 96-well plates and
treated with AXO crude extract (2.0mg/mL), DMSO
(1.6%), or phorbol 12-myristate 13-acetate (PMA;
Sigma-Aldrich) (10nM) for 72 h. Next, cells were col-
lected on slides prepared by cytospin centrifugation at
200g for 5min and stained using Leishman stain
(Sigma-Aldrich) according to the manufacturer’s pro-
tocol. The morphological analysis was performed
using the EVOS FL Auto 2 Cell Imaging System
(Invitrogen).
Analysis of cell cycle by flow cytometry
HL-60 cells (1 3 105/well) were seeded in 48-well plates
and treated with AXO crude extract (2.0mg/mL),
DMSO (1.6% and 10%), or PMA (10nM) for 72 h.
The cell cycle phase distribution was studied by quanti-
tation of DNA content. Cells were collected, centri-
fuged, washed with 13 PBS, and fixed with 70%
ethanol overnight at 4C. Then, after removing ethanol
and washing twice with PBS, cells were exposed to
100mL RNase A (100mg/mL; Sigma-Aldrich) for 1 h
at 37C, and stained with 200mL propidium iodide (PI)
(100mg/mL; Sigma-Aldrich) in the dark for 15min at
4C. The DNA content and cell cycle distribution were
analyzed by FACSCalibur flow cytometer (Becton
Dickinson, Oxford, UK), and the data were analyzed
utilizing Cell Quest software. At least 1 3 104 events
were acquired for each sample.
Nitroblue tetrazolium reduction assay
HL-60 cells (2 3 104/well) were seeded in 96-well plates
and treated with AXO crude extract (2.0mg/mL) or
DMSO (1.6%, as a positive control) for 72 h. Next, cells
were incubated with 2mg/mL nitroblue tetrazolium
(NBT) solution (Sigma-Aldrich) at 37C for 30min.
Then, the percentage of cells containing intracellular
blue–black formazan deposits was determined. In each
count, at least 200 cells were inspected using the EVOS
FL Auto 2 Cell Imaging System.
Detection of CD11b and CD14 by flow cytometry
HL-60 cells (1 3 105 cells/well) were seeded in 48-well
plates and exposed to AXO crude extract (2.0mg/mL),
DMSO (1.6%), or PMA (10nM) for 72h. Cells were col-
lected, centrifuged, washed twice with precooled PBS, and
incubated with direct Alexa Fluor 488-labeled anti-CD11b
antibody or phycoerythrin (PE)-labeled anti-CD14 anti-
body (BD Pharmingen, Buccinasco, Milan, Italy) on ice
on rotating platform in the dark. After 30min, cells were
washed twice and analyzed by FACSCalibur flow cyt-
ometer (Becton Dickinson), and the data were analyzed
utilizing Cell Quest software. At least 1 3 104 events were
acquired for each sample. Expression of cell marker was
determined by comparison with isotype control signal.
RNA extraction and real-time reverse transcription
polymerase chain reaction
Total RNA was isolated using RNeasy Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
instructions. The amount of RNA extracted was deter-
mined using the Nanodrop 2000 instrument (Thermo
Fisher Scientific). Complementary DNAs (cDNAs)
were produced from 300ng of RNA from each sample
using the QuantiTect Reverse Transcription Kit
(Qiagen) according to the manufacturer’s instructions.
Real-time reverse transcription polymerase chain reac-
tion (RT-PCR) was performed using TaqMan Gene
Expression Assays (Applied Biosystems, Foster City,
CA, USA) (Table 1). Two microliters of the diluted
cDNA were amplified in a final volume of 25mL with
13 TaqMan Gene Expression Master Mix (Applied
Biosystems). Thermal cycling consisted of 2min at
95C, 40 cycles at 95C for 15 s, and 60C for 1min. All
real-time PCR reactions are performed in triplicate. No
reverse transcriptase (no RT) control and a cDNA free
negative control were included during each run. Real-
time PCR and data collection were performed on Bio-
Rad CFX96 System Cycler Instrument (Bio-Rad
Laboratories). The relative expressions of mRNAs were
calculated using the comparative 2–DDCt method8 and
normalized against the geometric average expression of
HPRT1 and YWHAZ housekeeping genes.
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Statistical analysis
All experiments were performed in triplicate and
repeated at least twice. The SPSS software (version 20)
was used for statistical analysis. Data are presented as
the median and the interquartile range (IQR). Normal
distribution was assessed by the Kolmogorov–Smirnov
test. Since data were not normally distributed, they
were analyzed using the nonparametric Kruskal–Wallis
test, followed by Dunn–Bonferroni’s post hoc analysis.
Significance was accepted at p\ 0.05.
Results
Effects of the AXO extract on metabolic activity of
HL-60 and KG-1a cells
First, the effects of AXO crude extract were tested on
the metabolic activity of HL-60 and KG-1a cells using
the MTT assay. Both cell lines were treated for various
times (24–72h) with various doses of AXO extract
(0.25–2.00mg/mL). DMSO (10%) was used as a posi-
tive cytotoxic control.
As shown in Figure 1(a), AXO extract significantly
reduced HL-60 metabolic cell activity from 24 to 72h
compared to untreated cells. In fact, after 72 h treat-
ment, metabolic activity was reduced between 40% and
50%. However, AXO extract slightly reduced KG-1a
metabolic cell activity at 72 h at a concentration of
2.0mg/mL (Figure 1(b)). In fact, after 72 h treatment,
metabolic activity was reduced less than 20%. Since
preliminary data showed that AXO extract is particu-
larly effective on HL-60 cells, we decided to carry fur-
ther investigations using the HL-60 cell line.
AXO extract reduces HL-60 cell proliferation
The antiproliferative effects of AXO extract on HL-60
cells were also evaluated by the Trypan blue assay. As
shown in Figure 2(a) and (b), AXO extract significantly
reduced the cell number of HL-60 cells after 48 h. At
72 h, a dose-dependent effect was observed with growth
inhibition of 15%, 24%, 32%, and 50% for 0.25, 0.50,
1.00, and 2.00mg/mL, respectively, compared to
untreated cells. We also found that growth inhibition
caused by AXO extract treatment is not due to
decreased cell viability (Figure 2(c)).
Based on the data obtained, to investigate the possi-
ble anticancer effects of the A. mexicanum extract, we
decided to perform all the subsequent experiments by
incubating HL-60 cells with the concentration of
2.0mg/mL for 72 h.
HL-60 cells treated with AXO extract show G0/G1
arrest
HL-60 cells incubated with DMSO (1.6%) and PMA
(10nM) were used as positive controls for
Table 1. TaqMan Gene Expression Assays.
Gene Assay ID Catalog number
CDKN1A Hs00355782_m1 4331182
CDKN2C Hs00176227_m1 4331182
c-MYC Hs00153408_m1 4331182
SPI1 Hs02786771_m1 4331182
CEBPA Hs00269972_s1 4331182
CEBPB Hs00270923_s1 4331182
CEBPE Hs00357657_m1 4331182
HPRT1 Hs02800695 4331182
YWHAZ Hs01122445_g1 4331182
Figure 1. Effects of the axolotl (AXO) Ambystoma mexicanum
crude extract on metabolic activity of (a) HL-60 and (b) KG-1a
cells. Cells were treated with AXO or DMSO extract as
indicated for 72 h. Metabolic activity was calculated and data are
presented as median and interquartile range (error bars; n = 3
independent experiments carried out in triplicate), and were
analyzed using nonparametric Kruskal–Wallis, followed by
Dunn–Bonferroni’s post hoc analysis (*p\0.05; **p\0.001).
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differentiation, as well as with AXO extract. As shown
in Figure 3(a) and (b), flow cytometry analysis indi-
cated that among the untreated cells, 58.2% were dis-
tributed in G0/G1 phase, 26.4% were accumulated in S
phase, 13.1% were in G2/M phase, and only 2.3% were
in sub-G0/G1 phase. Incubation of HL-60 cells with
AXO extract (2.0mg/mL) for 72 h resulted in a marked
increase of cells in the G0/G1 phase (75.1%), with con-
comitant loss of S (16.8%) and G2/M (7%) phases.
AXO extract induces partial granulocytic
differentiation in HL-60 cells
The morphologic changes of cells treated with AXO
extract were viewed by Leishman staining. HL-60 cells
incubated with DMSO (1.6%) and PMA (10nM) were
used as positive controls for granulocytic and monocy-
tic differentiation, respectively. Untreated cells showed
typical myeloid leukemia cell morphology with a small
Figure 2. Effects of the axolotl Ambystoma mexicanum (AXO)
crude extract on (a) cell number, (b) relative cell growth
(percentage of cell number of treated cells relative to untreated
cells), and (c) cell viability of HL-60 cells. Cells were treated
with AXO extract as indicated for 24, 48, and 72 h. The number
of viable cells was determined by Trypan blue exclusion. Data
are presented as median and interquartile range (error bars;
n = 2 independent experiments carried out in triplicate), and
were analyzed using nonparametric Kruskal–Wallis, followed by
Dunn–Bonferroni’s post hoc analysis (*p\0.05; **p\0.001).
Figure 3. Effects of AXO extract (2.0mg/mL) treatment on
cell cycle distribution in HL-60 cells after 72 h. (a) Histogram
plots of flow cytometry analysis performed in HL-60 cells. (b)
Graph summarizing the cell cycle distribution. DMSO (1.6%) and
PMA (10 nM) were used as positive control for granulocytic and
monocytic differentiation, respectively. Data are presented as
median and interquartile range (error bars; n = 2 independent
experiments carried out in triplicate), and were analyzed using
nonparametric Kruskal–Wallis, followed by Dunn–Bonferroni’s
post hoc analysis (*p\0.05; **p\0.001).
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nucleus/cytoplasm (N/C) ratio and a small rim of baso-
philic cytoplasm, while AXO extract (2.0mg/mL)
increased the N/C ratio in HL-60 cells at 72 h (Figure
4(a)). The NBT assay was performed to detect the pro-
duction of oxidative burst enzyme expression during
the cell differentiation. As shown in Figure 4(b), NBT
positive cells were increased after treatment by AXO
extract (2.0mg/mL) for 72 h.
To further characterize the differentiation mediated
by AXO extract, flow cytometry analysis for myelomo-
nocytic markers CD11b and CD14 was performed.
HL-60 cells incubated with DMSO (1.6%) and PMA
(10nM) were used as positive controls for granulocytic
and monocytic differentiation, respectively. An increase
in the presence of CD11b-positive cells was observed in
HL-60 cells treated with AXO extract (2.0mg/mL) for
72 h, whereas the proportion of CD14-positive cells did
not change (Figure 5(a) and (b)). These findings suggest
that AXO extract is inducing granulocytic differentia-
tion in HL-60 cells in vitro.
Effects of AXO extract treatment on gene expression
in HL-60 cells
To investigate the molecular mechanisms by which
AXO extract may alter the cell cycle progression and
the differentiation state of HL-60 cells, the expression
of genes involved in the regulation of differentiation
(CEBPA, CEBPB, CEBPE, SPI1, and c-MYC) and
cell cycle (CDKN1A and CDKN2C) was quantified by
real-time RT-PCR analysis. HL-60 cells incubated with
DMSO (1.6%) were used as positive controls for gran-
ulocytic differentiation.
As shown in Figure 6(a) and (b), compared to
untreated counterpart, the treatment with AXO extract
(2.0mg/mL) increased the expressions of CEBPA,
CEBPB, CEBPE, SPI1, CDKN1A, and CDKN2C,
whereas it strongly reduced the expression of c-MYC
after 48 h. Figure 6(a) and (b) also shows that, after
72 h, the treatment with AXO extract further increased
the expressions of CEBPE and CDKN2C.
Discussion
In this study, the AXO crude extract exhibited
differentiation-inducing activity in human HL-60 cells,
a model system for studying human myeloid cell differ-
entiation. Our results suggest that AXO extract can
inhibit cell growth of HL-60 cells probably via inducing
G0/G1 phase arrest. Also, A. mexicanum extract
induces partial granulocytic morphological changes in
HL-60 cells.
Morphologically, HL-60 cells treated with AXO
resembled the appearance of ‘‘paramyeloid’’ cells with a
granulocyte-like nucleus but monocyte-like cytoplasm
similar to those described by Zinzar et al.9 These cells
were also described in patients with chronic myelomo-
nocytic leukemia.10 The cells lacked nuclear indenta-
tions and resembled ‘‘partially differentiated’’ HL-60
cells following treatment with arsenic trioxide.11 The
morphological changes including chromatin condensa-
tion and decreased nucleocytoplasmic ratio after AXO
treatment are similar to those seen following treatment
with organic plant extracts such as coumarin, arsantin
(a sesquiterpene lactone compound present in
Artemisia santolina), and the differentiation-inducing
agent, all-trans retinoic acid (ATRA).12–14
AXO-treated cells resemble early committed precur-
sors and as such would continue to divide before
acquiring a fully differentiated state. This is reflected in
the reduced rate of cell proliferation when compared to
Figure 4. AXO extract changes the morphology of HL-60
cells. (a) Leishman staining. The scale bar is 100mm. The images
were a representative of three independent experiments.
DMSO (1.6%) and PMA (10 nM) were used as positive controls
for granulocytic and monocytic differentiation, respectively. (b)
Nitroblue tetrazolium (NBT) reduction assay. Cells were
treated with AXO extract (2.0mg/mL) for 72 h. HL-60 cells
incubated with DMSO (1.6%) were used as positive controls for
granulocytic differentiation. Graph summarizes the percentages
of NBT positive cells. Data are presented as median and
interquartile range (error bars; n = 2 independent experiments
carried out in triplicate), and were analyzed using nonparametric
Kruskal–Wallis, followed by Dunn–Bonferroni’s post hoc
analysis (*p\0.05).
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untreated cells and an increase in the G0/G1 peak but
without complete inhibition of proliferation. Brown
et al.15 similarly reported that HL-60 cells treated with
ATRA committed to differentiation before cell cycle
arrest, with differentiated cells not restricted to any
particular stage of the cell cycle. These cells showed ele-
ments of innate immune responses, concomitant with
the acquisition of differentiated function despite
ongoing expansion of cell numbers.16 Such gain in
immune function of leukemia cells would be a benefit
to neutropenic patients with the disease. Moreover,
Figure 5. AXO extract–induced cell differentiation in HL-60
cells. (a) Cytometric analyses showing cell surface expression of
CD11b (left panels) and CD14 (right panels) in HL-60 cells
treated with DMSO (1.6%), PMA (10 nM), and AXO extract
(2.0mg/mL) for 72 h. (b) Graph summarizing both CD11b and
CD14 reactivity. Data are presented as median and interquartile
range (error bars; n = 2 independent experiments carried out in
triplicate), and were analyzed using nonparametric Kruskal–
Wallis, followed by Dunn–Bonferroni’s post hoc analysis
(*p\0.05; ns: not significant).
Figure 6. Differentially expression genes in response to AXO
extract treatment in HL-60 cells. Cells were treated with AXO
extract (2.0mg/mL) for indicated times. mRNA expression of
genes involved in (a) cell differentiation and (b) cell cycle
regulation was determined by real-time RT-PCR. HL-60 cells
incubated with DMSO (1.6%) were also used as positive
controls for granulocytic differentiation. Relative transcript
levels were determined using the 2–DDCt method and
normalized to HPRT1 and YWHAZ housekeeping genes.
Expressions in untreated cells were used as calibrators. Data are
presented as median and interquartile range (error bars; n = 2
independent experiments carried out in triplicate), and were
analyzed using nonparametric Kruskal–Wallis, followed by
Dunn–Bonferroni’s post hoc analysis (*p\0.05; **p\0.001).
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HL-60 cells induced to differentiate in response to
ATRA expressed the early differentiation marker
CD11b before halting cell division.17
The molecular mechanisms by which AXO extract
interferes with the cell cycle and induces differentiation of
HL-60 cells are yet unknown; however, differentiation of
HL-60 cells following treatment with AXO extract
increased expression of CDKN1A and CDKN2C.
Schwaller et al.18 found that granulocytic differentiation
induced by DMSO was accompanied by an increase in
the CDKN2C protein product p18 expression, suggesting
a direct role of this CDKi during myeloid differentiation.
Horie et al.19 showed that increased expression of p21, the
protein product of CDKN1A, is necessary for the differen-
tiation of HL-60 cells induced by ATRA. In our study,
AXO strongly induces CDKN1A, like ATRA-induced dif-
ferentiation but differently from DMSO-induced differen-
tiation. We speculate that AXO, similar to ATRA and
DMSO, induces granulocytic differentiation via the
mitogen-activated protein kinase (MAPK) signaling path-
ways. Previous studies have revealed that both ATRA
and DMSO induce HL-60 cells to differentiate into granu-
locytes via the extracellular-signal-regulated kinase (ERK)
phosphorylation signaling pathway. These reports indi-
cated that ERK1/2 phosphorylation is required to differ-
entiate HL-60 cells into granulocytes and macrophages.20
Importantly, AXO is inducing CDKN1A expression
in a p53-independent manner, as HL-60 cells lack a
functional p53 gene.19 This implies that AXO may pro-
vide means for relative cell cycle arrest and activation
of differentiation via CDKN1A in p53-null tumor cells.
Interestingly, p53-null tumor cells usually respond less
efficiently to direct cytotoxic chemotherapy.21
Expression studies of myeloid transcription factors,
here, complement the morphological and surface marker
picture, with AXO-exposed cells exhibiting a granulocyte-
like gene signature. Marchwicka and Marcinkowska22
showed that a strong and sustained expression of CEBPB,
when accompanied by the sustained expression of
CEBPE, leads to granulocytic differentiation,23 as also
seen here. AXO-treated HL-60 cells resulted in overex-
pression of SPI1 (PU.1) and c-MYC repression. The
downregulation of c-MYC by several compounds, includ-
ing nicotinamide, coumarin, and 4-hydroxyquinazoline,
causes arrest of leukemia cell proliferation and ultimately
sustains myeloid differentiation of AML cells.24 Taken
together, our findings show that AXO crude extract exhi-
bits antiproliferative and pro-differentiation action on
HL-60 cells (Figure 7).
Based on our results and previous studies,25 we
hypothesize that AXO extract might contain biologi-
cally active molecules similar to those derived from
Figure 7. Schematic representation of the effects of Ambystoma mexicanum crude extract in HL-60 cells. Possible mechanisms
include inducing cell differentiation and reducing cell proliferation. Green arrows represent increased expression, red arrows
indicate decreased expression, and black double-headed arrows indicate unchanged expression.
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other amphibians including biogenic amines, bufodie-
nolides (bufogenines and bufotoxins), alkaloids, pep-
tides, and proteins that are potentially useful as
anticancer agents. Interestingly, similar to AXO
extract, the steroid bufalin (isolated from amphibian
skin) seems to reduce the expression of c-MYC in HL-
60 cells. Whereas reduction of c-MYC in AXO results
in cell differentiation, bufalin induces apoptosis in HL-
60 cells. Further characterization of the extract in our
study might lead to identifying the active molecules,
analyzing their specific pharmacological and toxicolo-
gical effects, and the functional molecular mechanisms
involved, especially in ‘‘in vivo’’ models.26
Currently, isolating bioactive compounds from natu-
ral sources for producing pharmaceutical agents has
become the focus of much attention. In particular, these
compounds may act as promising sources for novel
therapeutic agents in the treatment of human cancers.4
Novel anticancer agents may arrest the cell cycle and
induce apoptosis and/or stimulate differentiation.27–30
AXO extract holds a lot of potential, particularly in
AML.
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